Figure 1.

Markov model. Patients remain in a health state (curved arrows) or move from 1 health state to another (straight arrows) based on transition probabilities. As patients cycle through the model, they accumulate costs and utilities expressed as QALYs. The Markov cycle length is 1 month and repeats over 10 years. During each cycle, patients are at risk for death from any cause, a bleeding event with or without joint damage. Gene therapy patients have an initial 1-year risk for failed therapy, resulting in transfer to the prophylaxis state.